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The oestrogen-dependent regulation 
of cell behaviour is realised by stimu-
lation of specific oestrogen receptors. 
The classical oestrogen receptors ERα 
and ERβ are transcription factors, and 
they modulate expression of hormon-
ally regulated genes, while the third 
one, GPER, is thought to be respon-
sible for the observed rapid, non-ge-
nomic cellular response. Oestrogen 
dependency is attributed to a number 
of cancers, including breast, ovarian 
and endometrial cancer; however, 
there is still growing evidence that 
melanoma should also be cited as 
a hormonally dependent tumour. This 
comes from the observations of gen-
der-related differences in melanoma 
progression and reports concerning 
the history of the malignant course 
of melanomas during pregnancy. Al-
though, the observations of oestrogen 
regulation of melanoma progression 
are controversial, the effect of oestro-
gen should not be neglected, as the 
skin possesses its own hormonal mi-
croenvironment. This aspect of mela-
noma progression should be taken 
under careful consideration as it may 
offer new therapeutic possibilities.
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Introduction
The biological effects of oestrogen are mediated by its binding to, and 
activation of, the oestrogen receptors ERα and ERβ [1, 2]. The observed acti-
vation of the G protein-coupled oestrogen receptor (GPER) after oestrogen 
stimulation implies that it could be the third oestrogen receptor [3–5]. ERα 
and ERβ are transcription factors interacting with the oestrogen response 
elements (EREs) located within the promoter regions of hormonally regu-
lated genes (Fig. 1). They participate in the formation of a multi-protein 
complex there, and as a result, they regulate the transcription process [6–8]. 
Both these receptors possess multi-domain structures and are composed of 
a highly conserved DNA-binding domain, a ligand-binding domain and two 
transcriptional activation functions AF1 and AF2. The DNA-binding domain 
is involved in recognition and binding of DNA and is located in the centre 
of the receptor protein, while the ligand-binding domain, engaged in recep-
tor-ligand interactions, is located in the COOH terminal. The NH
2
-terminal 
domain is the most variable domain regarding its sequence and length. This 
is also the region where the AF1 is located, while the AF2 is found in the 
COOH terminal. AF1 is constitutively activated and AF2 is hormone-depen-
dent [9, 10]. ERα and ERβ are soluble receptors that can shuttle between 
the cytoplasm and the nucleus, but they are found largely in the nucleus 
[11–13]. These receptors are products of distinct genes located on different 
chromosomes. Both types are synthesised in multiple splice variants; how-
ever, the biological activity of those variants has not been fully understood 
yet. For example, the shorter ERα isoforms lacking the NH
2
-terminal AF-1, 
named hERα-46 and hERα-36, have been isolated from different cell lines 
[14] but not from tissues. Their role in regulation of oestrogen effects in vivo 
is still unknown, although they represent an interesting research tool in vitro 
because they are able to heterodimerise with the full-length ERα, leading to 
inhibition of AF-1. It is also postulated that they can localise to plasma mem-
brane, and therefore they can be responsible for the rapid non-genomic oes-
trogen effects [15–18]. The third possible oestrogen receptor, GPER, shows 
many of the expected characteristics of a membrane oestrogen receptor. 
According to study results suggesting the constitutive internalisation of 
plasma membrane GPER [19, 20], its localisation seems to be mostly intra-
cellular [4, 21]. It belongs to the G protein-coupled receptor (GPCR) with sev-
en transmembrane domains. Its activation leads to the generation of cyclic 
AMP (cAMP), and it is thought to be responsible for the rapid oestrogen-me-
diated activation of Src-dependent signalling pathway leading to extracellu-
lar signal-regulated kinases (ERKs) activation [22–25]. There are some results 
suggesting that this signalling pathway activation is an effect of GPCR cross-
talk with epidermal growth factor receptor (EGFR) [26], insulin-like growth 
factor receptor (IGFR) [27] and α5β1 integrin [28] (Fig. 1). The potential role 
of insulin-like growth factor-1 (IGF-1) in the regulation of GPER expression 
was evaluated by de Marco et al. [29]. The GPER association with non-ge-
nomic oestrogen action has been postulated for more than 10 years, but it 
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is still controversial, and there are still suggestions that it 
does not act as an oestrogen receptor at all [30]. However, 
the previously suggested hypothesis that GPER and ER act 
in concert in some signal transduction pathways has not 
been totally excluded [21].
Oestrogen in melanoma progression
Although it is commonly accepted that oestrogen reg-
ulates the growth and differentiation of normal and neo-
plastic tissues, including breast, ovarian and endometrial 
tumours [31], there is growing evidence of its influence 
on melanoma progression as well. There are case reports 
showing a poor prognosis for women in whom melano-
ma has developed during pregnancy [32, 33] and clinical 
observations demonstrating that women with melanoma 
have better prognosis than men [34]. There are also pre-
clinical data showing that oestrogen and its metabolites 
may influence the course of melanoma progression [35, 
36]. Nevertheless, observations of the influence of oestro-
gen on melanoma cells are controversial.
Melanomas originate from melanocytes, melanin-pro-
ducing cells, found in the deep layer of the epidermis [37] 
and are considered as highly malignant tumours with an 
aggressive nature manifesting in the potential for early dis-
ease dissemination [38], which may come from very small 
tumour masses [39]. However, the formation of metastases 
in melanoma stage I and II is rarely observed. The early detec-
tion of neoplastic changes (in stage I and II) based on mole 
evaluation by ABCDE criteria (Asymmetry in shape, Bor-
der irregularities, Colour heterogeneity, Diameter > 6 mm 
and Evolution [history of morphologic changes of the 
lesion] [40]) significantly improve the patient survival rate. 
Localised lesions in the early stages are usually curable by 
surgical resection. Increased lesion thickness and the pres-
Fig. 1. The mechanism of oestrogen action. The binding of E2 to the classical ERα or ERβ receptors leads to transcription of hormone-de-
pendent genes. The third possible ER, GPER, is a membrane receptor, which is suggested to be responsible for non-genomic E2 action. Acti-
vated GPER triggers the clustering of α5β1 integrins, which in turn leads to the assembly of fibronectin matrix. Oestrogen action via GPER 
is enhanced by the presence of the IGFR-ligand complex, which results in stimulation of the GPER gene transcription. The GPER activation 
promotes also transactivation of EGFR, resulting in activation of signalling pathway, also leading to GPER gene transcription. Another pos-
sible way of E2 action is through hERα-36/-46, which are shorter isoforms of ERα localised in plasma membrane. Their function is not yet 
fully understood
α5β1 – integrin receptor, AC – adenyl cyclase, EGFR – epidermal growth factor receptor, ER – endoplasmic reticulum, ER – oestrogen receptor (α and β), ERE 
– oestrogen response element, ERK1/2 – extracellular signal-regulated kinases 1/2, FN – fibronectin, GPER – G protein-coupled oestrogen receptor, HB-EGF – 
heparin-binding epidermal growth factor-like growth factor, HSP90 – heat shock protein 90, IGF – insulin-like growth factor, IGFR-insulin-like growth factor 











































ence of metastases both in regional lymph nodes or dis-
tant tissues are poor prognostic indicators [41, 42]. A large 
number of risk factors that influence melanoma incidence 
and mortality rates have already been recognised. These 
factors are generally subdivided into two groups: genetic 
and environmental, which closely interact with each other 
[40, 42, 43]. 
An interesting aspect of melanoma progression, i.e. 
gender-related influence, has been addressed by many au-
thors since the late 1960s [44]. Generally, it has been sug-
gested that the disease develops more rapidly in men than 
in women, and that women have more favourable prog-
nostic tumour characteristics than men [45–53]; however, 
geographical diversity in gender-related melanoma behav-
iour has also been observed [54]. There have also been 
studies analysing the presence of satellite and in-transit 
metastasis in male and female patients with cutaneous 
melanomas. For example, one of them, published by Meier 
et al. [39], showed the difference in frequencies of satellite 
and in-transit metastases between men (16.7%) and wom-
en (26.4%). Meier et al. [39] also observed that more fre-
quently in men than in women the regional lymph nodes 
were the main sites of metastases. This observation was 
consistent with previous reports showing a stronger ten-
dency in men towards tumour progression, from the stage 
of the primary tumour into the regional lymph nodes me-
tastases [39]. Such gender-related tendencies in melano-
ma progression are thought to be influenced by endocrine 
status. Because skin has its own capacity to produce ste-
roids, including oestrogen, its subjection to sex hormones 
should not be underestimated. Consequently, it was pos-
tulated by de Giorgi et al. [55] that melanomas should be 
at least cited among hormone-related neoplasms. These 
observations are also supported by analysis of oestro-
gen receptor (ER) expression in melanomas. It has been 
shown that ER expression is diverse between the tumour 
lesion and the healthy skin surrounding them. Moreover, 
a statistically significant difference in the mean oestrogen 
receptor (ER) concentrations in male versus female origin 
melanomas was found [56]. However, such reports are in 
contradiction with earlier studies indicating that the in-
cidence of melanomas with detectable ER (refers to ERα 
– primarily discovered ER) is low, suggesting that the po-
tential clinical usefulness of the ER assays in melanoma 
might be limited [57]. However, this was stated before the 
discovery of the second oestrogen receptor – ERβ. 
ERβ has been shown potentially to have a suppressive 
effect in a variety of human tumours, such as breast, pros-
tate, colon and ovarian cancers [58]. ERβ is suggested to 
have a protective function against tumour formation be-
cause it reduces uncontrolled cell proliferation by increas-
ing apoptotic activity [34, 59]. Studies of melanoma cells 
have led to the conclusion that ERβ expression is altered 
in relation to the increasing depth of their invasion and 
to the diversified specificity of the tumour microenviron-
ment [60]. These observations were further confirmed by 
de Giorgi et al. [61]. Based on the analysis of a small group 
of patients (14 patients, including 2 melanocytic nevi), 
they showed markedly decreased expression of ERβ in the 
metastatic phase of the melanoma. Moreover, it has been 
reported that melanoma tumours form patients suffering 
from lymph node metastases possessed lower expres-
sion of ERβ compared with surrounding normal skin [61]. 
Recently published results of a study of 66 patients with 
melanoma have also confirmed previous observations 
and have shown that increased Breslow thickness was in-
versely associated with lower ERβ expression in malignant 
melanoma tumours, compared to the adjacent healthy 
skin. In accordance with these findings, observations of 
gender-related metastasis formation have shown greater 
ERβ expression in women than men [62]. The reports of 
predominant expression of ERβ in melanoma cells have 
been independently confirmed by the immunohistochem-
istry analysis made by Ohata et al. [63], which revealed 
that melanocytes of melanocytic nevi and malignant mel-
anoma cells express ERβ but not ERα. Interestingly, it has 
been suggested by those authors that ERβ cannot be used 
as a marker of melanoma progression. Ohata et al. [63] as-
certained that the intensity of staining for ERβ, reflecting 
its level of expression, is not influenced by sex or by the se-
rum levels of oestrogen, and it is very similar regardless of 
the age of female patients (ranging from 1 to 79 years) [63]. 
Some assumptions of the linkage between hormonal 
stimulation and ER expression in melanomas have been 
based on reports concerning melanoma development 
during pregnancy. In 1998 Grin et al. [64] published their 
critical review gathering information on controlled clinical 
trials assessing the effect of pregnancy on the prognosis 
of melanomas, and epidemiological data evaluating the 
risk of melanoma after exposure to oral contraceptives 
and hormonal replacement therapy. They concluded that 
pregnancy before, during or after the diagnosis of mela-
noma did not appear to influence 5-year survival rates. 
In their opinion, exposure to oral contraceptives and 
hormonal replacement therapy also did not appear to in-
crease the risk of melanoma [64] as was observed in the 
case of other hormone-dependent cancers such as breast, 
ovarian, endometrial or prostate [65]. Since 1998, several 
reports revealing significant decreases in ERβ immunore-
activity in congenital nevi, in comparison to normal tissue 
and dysplastic nevi from pregnant women, have been 
published. All of them have suggested that nevi possess 
the capacity to be oestrogen-responsive. It was conclud-
ed that pregnancy and degree of atypia were associated 
with enhanced ERβ expression, with the exception of con-
genital nevi, in which the expression lowered [66]. Parallel 
observations have been made by Nading et al. [67] in the 
case of a young woman with large congenital nevi. Biopsy 
sample showed a decrease in nuclear staining for ERβ. It 
has been postulated that ERβ may have a suppressant ef-
fect in melanomas [67]. The use of oral contraceptives and 
hormonal replacement therapy and their association with 
the Breslow thickness of cutaneous melanomas has also 
been continuously analysed since the publication by Grin 
et al. [64]. Koomen et al. [68] showed that there is no such 
statistically significant association; however, decreased 
Breslow thickness among women using oestrogen, espe-
cially among older women, has not been excluded [68]. 
The results of Tang et al. [69] also failed to support the 
role of menopausal hormone therapy in the development 
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of non-melanoma skin cancer or melanomas in postmeno-
pausal women. Nevertheless, ERβ was suggested as a use-
ful prognostic marker for neoplasia and prognosis in cuta-
neous malignant melanoma.
Summary
In conclusion, it should be taken into consideration 
that, despite the fact that there is a great deal of contra-
diction in the results concerning the role of oestrogen in 
the course of melanomas, there is still growing clinical and 
preclinical evidence suggesting that oestrogen stimula-
tion does have an influence on melanoma cells and may 
regulate their metastatic progression. Some new aspects 
of this problem are still being addressed by a number of 
researchers. Gathering those results will give a new pic-
ture of melanoma cell susceptibility to microenvironment 
agents. It is well known that melanomas represent an im-
portant public health problem in terms of morbidity and 
mortality. Therefore, efforts should be undertaken aimed 
at both primary prevention (risk reduction) and secondary 
prevention (early detection, which is critical to improve the 
clinical outcome of this disease) [70]. The growing focus 
on the role of oestrogen in melanoma progression is as-
sociated with the fact that there are still no effective and 
satisfying treatments for melanoma tumours. Despite the 
large number of agents studied in advanced melanoma 
[71–73], the therapy standards have remained almost un-
changed and outcomes continue to be poor [74, 75]. For 
this reason, looking for new aspects of melanoma cell 
progression may serve as a starting point for finding novel 
methods of treatment. 
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